Carmat (ALCAR.PA) Stock Price
Carmat Price
Over the last 14 years Carmat grew revenue by 2.4% annually, reaching 7.00 M EUR. For Carmat, the net margin of -734.3% is up versus -410,700.1% a few years ago.
Carmat stock price
Carmat business model & stock analysis
Frequently asked questions about Carmat
The business model of Carmat SA is focused on the development and commercialization of innovative cardiovascular devices to address heart failure. Carmat SA has developed the world's most advanced total artificial heart (TAH), which aims to improve the prognosis and quality of life for patients suffering from end-stage biventricular heart failure. With its unique biocompatible design and integration of cutting-edge technologies, Carmat's TAH offers hope for patients awaiting heart transplantation. By combining expertise in biomedical engineering and cardiology, Carmat SA aims to revolutionize the field of heart failure treatment and provide long-term solutions for patients in need.
Carmat SA is primarily active in the medical device industry.
The main competitors of Carmat SA in the market include companies such as Medtronic PLC, Abbott Laboratories, Edwards Lifesciences Corporation, and SynCardia Systems, LLC.
Carmat SA, a leading French biomedical company, has a significant history and background. Established in 2008, Carmat aims to revolutionize cardiac medicine through its cutting-edge technology. The company's flagship product, the Carmat Total Artificial Heart (TAH), is an innovative solution for patients with end-stage biventricular heart failure. Designed to mimic the natural heart, the TAH offers hope to individuals otherwise awaiting heart transplantation. Carmat SA combines expertise in biomechanics, robotics, and material science to develop this groundbreaking device. By addressing the global shortage of donor organs, Carmat SA strives to improve the quality of life for patients suffering from severe heart conditions.
Carmat SA, a leading biomedical company, has achieved several significant milestones. Firstly, the company successfully developed and received European approval for its cutting-edge biocompatible artificial heart (Aeson). This breakthrough medical device offers a potential life-saving solution for end-stage heart failure patients. Secondly, Carmat SA successfully performed clinical trials demonstrating the feasibility and safety of their artificial heart. Moreover, the company achieved the first human implantation of Aeson, which was an important milestone towards commercialization. These milestones highlight Carmat SA's commitment to innovative biomedical solutions and their pursuit of transforming the lives of patients suffering from heart failure.
Carmat SA is primarily present in France and the European Union (EU) region.
Carmat SA represents values of innovation, medical advancement, and patient care. With its corporate philosophy centered around improving the quality of life for individuals with end-stage heart failure, Carmat SA aims to provide a groundbreaking solution through its artificial heart technology. The company's relentless focus on research and development, collaboration with medical professionals, and commitment to excellence underscores its dedication to transforming the field of cardiac medicine. Carmat SA strives to enhance patients' well-being by offering a revolutionary cardiac solution that integrates seamlessly into their lives, emphasizing its commitment to both technological prowess and human compassion.
11 analysts currently rate the Carmat stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Carmat to generate revenue of 76.90 M EUR and earnings per share of -0.98 EUR.
The Carmat share (ALCAR.PA) is listed on 6 stock exchanges, including: Frankfurt (CXT.F), München (CXT.MU), Düsseldorf (CXT.DU), Paris (ALCAR.PA).
Carmat SA is a French company specializing in the development, manufacturing, and marketing of innovative therapy products for patients with severe heart failure. The company is headquartered in Vélizy-Villacoublay, a municipality in the southwest of Paris, and is listed on the Euronext Paris stock exchange. Carmat SA's business model consists of three main areas: research and development, production, and distribution. In the research and development area, the company focuses on the exploration and development of implantable artificial hearts as an alternative to conventional treatment methods for end-stage heart failure patients. It aims to prolong the lives and improve the quality of life of patients. The production area of Carmat SA encompasses the manufacturing of implantable artificial hearts that adhere to the highest standards to ensure their suitability for human use. The company employs state-of-the-art manufacturing methods and materials. The production is a complex task due to the high quality requirements and compliance with medical technology regulations. Carmat SA's distribution area is focused on introducing the implantable artificial hearts in selected global markets. The company collaborates closely with medical institutions and networks to promote widespread acceptance of this innovation. Carmat SA has a clear vision for the development of artificial hearts that can enable patients with severe heart failure to lead independent lives. By integrating cutting-edge technology and innovative design features, the treatment of heart failure is intended to be revolutionized. Carmat SA aims to be a leading provider of medical technology for the cardiology industry. The artificial hearts developed by Carmat SA make a significant contribution to patients with severe heart failure. In addition to the development of high-quality heart supplementation solutions, the company also focuses on continuous improvement and adaptation of its products to meet the patients' needs. To ensure the quality and longevity of its products, Carmat SA invests heavily in research and development. The company collaborates with leading experts in the fields of medicine and technology to keep its products at the forefront of technological advancements. In summary, Carmat SA is an innovative company specializing in the development, manufacturing, and marketing of implantable artificial hearts for patients with heart failure. Through its research and development, production, and distribution areas, the company effectively produces and sells its products. Carmat SA aims to increase its market share in the medical technology industry for cardiology and contribute to improving the quality of life for patients with heart failure.
The expected revenue of Carmat is 76.90 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Carmat is -22.25 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Carmat is currently -0.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Carmat stock.
The price-to-sales ratio (P/S) of Carmat is currently 0.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Carmat stock.
The Eulerpool Quality Score for Carmat is 4/10.
The ISIN of Carmat is FR0010907956. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Carmat is A1C017. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Carmat is ALCAR.PA. The ticker symbol is used to trade Carmat shares on the stock exchange.
Carmat stock
Carmat Peer Group
Carmat Ticker
Carmat FIGI
All fundamentals and in-depth analysis of Carmat
Our stock analysis for Carmat stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carmat. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.